Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5710042 | 0.85 | CA12 (0.40) | CA12CA1CA9CA2PDK1 | |
| SCHEMBL14645780 | 0.79 | CA12 (0.56) | CA12CA1CA9CA2PDK1 | |
| SCHEMBL21805912 | 0.79 | CA12 (0.56) | CA12CA1CA9CA2PDK1 | |
| SCHEMBL3991346 | 0.79 | CA12 (0.56) | CA12CA1CA9CA2PDK1 | |
| Hydrochloric Acid SCHEMBL29178584 | 0.78 | CA12 (0.55) | CA12CA1CA9CA2PDK1 | |
| Hydrochloric Acid SCHEMBL29178589 | 0.78 | CA12 (0.55) | CA12CA1CA9CA2PDK1 | |
| Hydrochloric Acid SCHEMBL29178585 | 0.78 | CA12 (0.55) | CA12CA1CA9CA2PDK1 | |
| SCHEMBL925416 | 0.77 | CA12 (0.40) | CA12CA1CA9CA2PDK1 | |
| SCHEMBL1150296 | 0.76 | CA12 (0.44) | CA12CA1CA9CA2PDK1 | |
| SCHEMBL29022309 | 0.76 | CA12 (0.44) | CA12CA1CA9CA2PDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778652-A2 | COMPOSITIONS AND METHODS COMPRISING PROTEINASE ACTIVATED RECEPTOR ANTAGONISTS | EntreMed, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060063930-A1 | Compositions and methods comprising proteinase activated receptor antagonists | ENTREMED, INC. | 2006-03-23 | — | — | US | disclosed |
| WO-2006023844-A2 | COMPOSITIONS AND METHODS COMPRISING PROTEINASE ACTIVATED RECEPTOR ANTAGONISTS | ENTREMED, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063930-A1 | Compositions and methods comprising proteinase activated receptor antagonists | F2RL1, PLAUR, F2R | CA12 2387/4885CA1 2189/4885CA9 2229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.